ReviewDrug design, development and therapy2020
Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab.
Review in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Investigating the role of health information technology in the control and management of Systemic Lupus Erythematosus (SLE): a systematic review.BMC medical informatics and decision making · 2022Pooled it
- Efficacy of belimumab in children with systemic lupus erythematosus.BMC pediatrics · 2026Observational
- Effectiveness and safety analysis of initial treatment with belimumab in childhood-onset systemic lupus erythematosus.Frontiers in immunology · 2026Article
- Progress of biological agents and CAR cell therapy in the treatment of common autoimmune diseases in children.Frontiers in pediatrics · 2026Review
- CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?Arthritis research & therapy · 2025Review
- Early-onset lupus nephritis.Clinical kidney journal · 2024Review
- Association of Race and Ethnicity With Medication Use for Pediatric Lupus in the Childhood Arthritis and Rheumatology Research Alliance Registry.ACR open rheumatology · 2022Article
- Distinct binding mode of BAFF antagonist antibodies belimumab and tabalumab, analyzed by computer simulation.Journal of molecular modeling · 2022Article
- Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: the BELNEPH study.Pediatric nephrology (Berlin, Germany) · 2022Article
- Recent advances in the treatment of systemic lupus erythematosus with belimumab in children.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2021Review
- Emerging B-Cell Therapies in Systemic Lupus Erythematosus.Therapeutics and clinical risk management · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Belimumab (Benlysta
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.